About This Page
This is a clinician-written, evidence-based guide aligned to the MCC Examination Objectives. It is structured by clinical presentation — the way the MCCQE tests and the way patients actually present. Management reflects current Canadian guidelines (CMA, CFPC, CPS). Always cross-reference with institutional protocols and clinical judgment.
The Bottom Line
- Do not ignore an incidental abnormal CXR — compare with prior imaging, assess cancer/infection/TB risk, and arrange a documented follow-up plan
- Pulmonary nodule risk depends on size, growth, spiculation, upper-lobe location, smoking/radon/asbestos exposure, age, prior cancer, and immunocompromise
- CXR cannot adequately characterise most nodules; CT chest is the key next test for suspicious or indeterminate nodules
- Abnormal CXR with haemoptysis, weight loss, recurrent pneumonia, hoarseness, lymphadenopathy, or smoking history requires urgent malignancy workup
- In Canada, provincial lung cancer screening/diagnostic pathways may apply; low-dose CT screening is targeted to high-risk populations, not general screening
Approach to the Presentation
A pulmonary nodule or abnormal CXR may be found incidentally, during investigation of cough/dyspnoea/haemoptysis, pre-operatively, or through lung screening. The core MCCQE1 task is not to memorise every radiology follow-up interval but to risk-stratify safely: confirm the finding, compare with old imaging, identify symptoms and risk factors, decide whether infection follow-up versus immediate CT is appropriate, and ensure closed-loop follow-up. A persistent opacity after pneumonia, a solitary pulmonary nodule in a smoker, cavitation with systemic symptoms, or a mediastinal mass with compressive symptoms all require more than reassurance.
Differential Diagnosis
| diagnosis | likelihood | key features | distinguishing test |
|---|---|---|---|
| Primary Lung Cancer | must-not-miss | Age, smoking, radon/asbestos, haemoptysis, weight loss, persistent cough, hoarseness, recurrent pneumonia, clubbing, spiculated or upper-lobe nodule | CT chest with contrast where appropriate + tissue diagnosis via bronchoscopy, CT-guided biopsy, or surgical pathway |
| Metastatic Malignancy | must-not-miss | History of cancer, multiple nodules, systemic symptoms; common primaries include breast, colorectal, renal, melanoma, sarcoma | CT chest/abdomen/pelvis or staging imaging; biopsy if diagnosis will change management |
| Tuberculosis | must-not-miss | Upper-lobe infiltrate/cavitation, chronic cough, haemoptysis, fever, night sweats, weight loss, exposure risk, immunocompromise | Sputum AFB smear/culture and NAAT; CT chest; public health notification if suspected |
| Mediastinal Mass | must-not-miss | CXR mediastinal widening/mass, cough, dyspnoea, stridor, dysphagia, facial/upper limb swelling, B symptoms; anterior mass: thymoma, lymphoma, germ cell tumour | CT chest with contrast; tumour markers or biopsy depending on compartment and suspected pathology |
| Pneumonia / Non-resolving Consolidation | common | Fever, cough, sputum, focal infiltrate. Persistent consolidation after treatment raises malignancy, TB, obstruction, or atypical infection | CXR response to therapy; repeat imaging in higher-risk patients; CT if persistent or atypical |
| Benign Granuloma / Old Infection | common | Calcified stable nodule, prior granulomatous disease, histoplasmosis/TB exposure, no growth on serial imaging | Comparison with prior imaging; CT calcification pattern and stability |
| Atelectasis / Mucus Plug / Obstructing Lesion | common | Volume loss, elevated hemidiaphragm, fissure displacement; may occur post-op or with tumour/foreign body obstruction | CXR comparison, CT chest, bronchoscopy if obstruction suspected |
| Artefact / Nipple Shadow / Skin Lesion | common | Apparent nodule over lower lung zones, symmetric or superficial, disappears with nipple markers or repeat view | Repeat CXR with nipple markers or CT if uncertainty persists |
| Hamartoma | less common | Benign nodule, may show popcorn calcification or fat density, often incidental | CT features; follow-up or biopsy if not confidently benign |
| Sarcoidosis | less common | Bilateral hilar lymphadenopathy, cough/dyspnoea, erythema nodosum, uveitis, arthralgia; often young/middle-aged adult | CXR/CT pattern, biopsy of accessible node/tissue if diagnosis uncertain or treatment needed |
| Interstitial Lung Disease | less common | Reticular opacities, reduced volumes, chronic dyspnoea, dry cough, crackles, clubbing, autoimmune or occupational exposure | HRCT and full PFTs with DLCO |
Red Flags & Key History
Symptoms
Haemoptysis, weight loss, persistent cough, hoarseness, chest pain, recurrent pneumonia
Smoking/vaping, radon, asbestos, silica, diesel exposure, prior thoracic radiation, family history
Fever, night sweats, TB exposure, shelter/incarceration, high-incidence country exposure, immunocompromise
Facial swelling, venous distension, stridor, dysphagia — mediastinal mass/SVC obstruction
Autoimmune symptoms, occupational exposures, birds/mould — ILD or hypersensitivity pneumonitis
Asymptomatic incidental nodule with benign calcification and stability on old imaging
Signs
Clubbing, cachexia, lymphadenopathy, hoarseness
Supraclavicular node — high concern for malignancy
Bilateral hilar lymphadenopathy with erythema nodosum/uveitis — sarcoidosis pattern
Fine bibasal crackles and clubbing — ILD
Signs of SVC obstruction: facial/upper extremity swelling, dilated chest wall veins
Approach to Investigation
First-line
Compare with previous imagingStability over years strongly supports benignity; growth is concerning. Always document comparison and follow-up plan
Repeat or additional CXR views if artefact suspectedNipple markers/lateral view can clarify some apparent nodules, but suspicious findings should move to CT
CT chestKey test for indeterminate/suspicious nodules or abnormal CXR. Characterises size, density, calcification, spiculation, lymph nodes, cavitation, multiplicity, and resectability clues
Basic labs guided by contextCBC, calcium, renal function before contrast, inflammatory markers if infection suspected; not a substitute for imaging follow-up
Second-line
Sputum AFB/NAAT/cultureIf TB is possible; use airborne precautions for infectious presentations and involve public health
PET-CTFor intermediate-high risk nodules or staging suspected lung cancer when size and clinical context support use
Pulmonary function testingIf lung cancer surgery is possible, COPD/ILD suspected, or symptoms require physiologic assessment
Low-dose CT screening pathwayFor eligible high-risk patients through provincial programmes where available; screening is not a diagnostic shortcut for symptomatic patients
Specialist
Biopsy pathwayBronchoscopy/EBUS for central lesions or nodes; CT-guided biopsy for peripheral lesions; surgical biopsy/resection for selected high-risk lesions
Respirology / thoracic surgery / oncology referralSuspicious CT features, high-risk patient, persistent unexplained opacity, mediastinal mass, recurrent haemoptysis, or suspected cancer
Management Principles
Ontario Health/Cancer Care Ontario lung diagnostic pathways + Canadian Thoracic Society pulmonary nodule framework1
Risk-stratify and close the loop
- Document symptoms, risk factors, CXR/CT findings, prior imaging comparison, and explicit follow-up date/test
- Low-risk clearly benign features: reassure or surveillance per radiology recommendation
- Indeterminate nodule: CT-based surveillance or PET/biopsy depending on size/risk/radiology recommendation
- High-risk/suspicious: urgent respirology or lung diagnostic pathway referral
2
If infection is possible
- Treat pneumonia when clinical features support it, but arrange follow-up imaging for persistent symptoms or higher-risk patients
- Do not attribute recurrent same-lobe pneumonia to infection alone — consider obstruction or malignancy
- Suspected TB: isolate if infectious, collect sputum tests, notify public health, and involve TB specialists
3
Cancer prevention and screening
- Smoking cessation, radon mitigation advice where relevant, occupational exposure history, vaccination/health maintenance
- Consider referral to provincial lung cancer screening programmes for eligible high-risk individuals; symptomatic abnormalities need diagnostic workup, not screening
Complications & Pitfalls
- No follow-up system: The most dangerous nodule is the one nobody follows. Closed-loop documentation is essential.
- Pneumonia mask: Lung cancer can present as non-resolving or recurrent pneumonia, especially in smokers.
- CXR limitation: A normal or vague CXR cannot fully characterise a suspicious nodule; CT is often the decisive next step.
- Confusing screening and diagnosis: Low-dose CT screening is for eligible asymptomatic high-risk people; symptomatic patients need diagnostic evaluation.
- Ignoring TB/public health: Cavitary upper-lobe disease with systemic symptoms requires TB precautions and notification.
MCCQE1 Exam Tips
- 1Incidental nodule: first compare with old imaging; next is CT characterisation if indeterminate or suspicious
- 2Spiculated upper-lobe nodule in a smoker = lung cancer until proven otherwise
- 3Persistent opacity after pneumonia treatment needs repeat imaging/CT, especially in older smokers
- 4Cavitary upper-lobe lesion + night sweats/weight loss = TB testing and public health steps
- 5Mediastinal mass with facial swelling/venous distension = SVC syndrome risk and urgent workup
- 6Benign calcification/stability lowers risk, but lack of previous imaging means you still need a plan
- 7CanMEDS manager/professional: documenting and tracking follow-up is a patient-safety intervention, not admin trivia
practicetest your knowledge on pulmonary nodule / abnormal cxrApply what you've learnt with MCCQE1-style questions from the iatroX Q-Bank — respiratory and beyond.
open q-bank